Append Medical Presented its First of its Kind NO IMPLANT LAA Closure Device in Major Global Conferences
Over the past quarter, Append Medical’s revolutionary LAA closure device was presented in two of the most important conferences in Cardiology.
Prof. Horst Sievert, MD, a leading expert in LAA closure, presented new technologies for LAA closure in a presentation titled “The Spectrum of LAA Closure Technology Current and Emerging Devices” during TCT (Transcatheter Cardiovascular Therapeutics) 2019 conference held in San Francisco. Prof. Sievert reviewed the latest emerging technologies and underscored Append Medical’s solution for its innovativeness. TCT is the world’s largest and most important educational meeting specializing in interventional cardiovascular medicine with more than 11,000 attendees from over 100 countries.
Recently, Append Medical’s CEO, Dr. Zachi Berger, presented proof of concept of its new generation NO IMPLANT LAA closure device during the CSI LAA 2019 conference in Frankfurt, a conference specializing on the LAA closure devices. Append Medical was invited by the conference organizers to present its novel solution.
The Append Medical system is designed to prevent blood clot leakage by achieving complete LAA closure thus reducing the risk of stroke in patients with non-valvular atrial fibrillation. Its unique design may allow it to mitigate device-related thromboembolism risk by leaving minimal foreign material at the closure site. The procedure itself is intended to be simple, fast and requiring less pre-procedure planning.
The Append Medical solution is targeting the LAA closure market, which is the second-fastest growing segment of the medical device market and estimated to exceed $10B within several years.
Append Medical is a pre-clinical phase, privately held company operating as part of MEDX Xelerator in Israel. Its major shareholders are MEDX Ventures, Boston Scientific Inc, Intellectual Ventures and the company founders.
Back
